Intralesional Methotrexate versus Intralesional Triamcinolone acetonide in Treatment of Resistant Localized Alopecia Areata | ||||
| Al-Azhar International Medical Journal | ||||
| Volume 2025, Issue 3, March 2025, Page 122-128 PDF (643.52 K) | ||||
| Document Type: Original Article | ||||
| DOI: https://doi.org/10.21608/aimj.2025.446474 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| Ahmed Mohammad Abdel Aal1; Ahmed Shawky Abdelaty2; Alshaimaa Abdullah Muhammad* 3 | ||||
| 1Professor of Dermatology, Venereology and Andrology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt | ||||
| 2Associate Professor of Dermatology, Venereology and Andrology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt | ||||
| 3MBBCh., Faculty of Medicine, Al-Azhar University, Cairo, Egypt. | ||||
| Abstract | ||||
| Background: Noncicatricial hair loss is the hallmark of the common autoimmune hair condition alopecia areata(AA). Although AA often manifests as isolated patches on the face and scalp, it can affect any part of the body that bears hair, potentially resulting in much more widespread involvement. Aim and objectives: To evaluate the efficacy of intralesional methotrexate against intralesional triamcinolone acetate in treating patients with localized resistant alopecia areata at the dermatology department. Patients and methods: The current study was conducted on 40-participants in the outpatient clinic of Dermatology and Venereology Departments of Al-Hussein University Hospitals, Al-Azhar University,Cairo from July 2021 to January 2023. Twenty patients were selected for each group. Intralesional injections in alopecia areata patches were administered to both groups using a 30-gauge needle attached to an insulin syringe. Each group had a maximum of four injections spaced three weeks apart. Results: Clinical Improvement, Density, and Hair Thickness were not significantly different between the two groups (p=0.776, 0.569, and 0.125, respectively). The pain sensation and the number of sessions were significantly lower in the methotrexate group, with p-values of<0.001&0.014, respectively. Conclusion: No statistical difference was found between the results for the groups receiving methotrexate and triamcinolone. Pain was major side effect, and higher number of sessions were needed in Triamcinolone group with statistically significant difference compared with Methotrexate group. As an alternative to intralesional triamcinolone, intralesional MTX shows promise as a treatment for localized resistant AA. | ||||
| Keywords | ||||
| Methotrexate; Intralesional triamcinolone acetonide; Alopecia areata | ||||
|
Statistics Article View: 1 PDF Download: 1 |
||||
